TR201818771T4 - Bilişsel Bozuklukların Tedavisinde Kullanıma Yönelik Bileşikler - Google Patents

Bilişsel Bozuklukların Tedavisinde Kullanıma Yönelik Bileşikler Download PDF

Info

Publication number
TR201818771T4
TR201818771T4 TR2018/18771T TR201818771T TR201818771T4 TR 201818771 T4 TR201818771 T4 TR 201818771T4 TR 2018/18771 T TR2018/18771 T TR 2018/18771T TR 201818771 T TR201818771 T TR 201818771T TR 201818771 T4 TR201818771 T4 TR 201818771T4
Authority
TR
Turkey
Prior art keywords
treatment
compounds
cognitive disorders
formula
definitions
Prior art date
Application number
TR2018/18771T
Other languages
English (en)
Inventor
E Donello John
J Schweighoffer Fabien
M Luhrs Lauren
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of TR201818771T4 publication Critical patent/TR201818771T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Konu olan buluş bir bilişsel bozukluğun tedavisinde kullanılmak üzere aşağıdaki Formül 1'de temsil edilen bir bileşiği veya onun farmasötik olarak kabul edilebilir bir tuzunu sağlar; burada Formül 1'deki semboller İstem 1'de anlatılan tanımlara sahiptir.
TR2018/18771T 2007-03-06 2008-03-04 Bilişsel Bozuklukların Tedavisinde Kullanıma Yönelik Bileşikler TR201818771T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89319607P 2007-03-06 2007-03-06

Publications (1)

Publication Number Publication Date
TR201818771T4 true TR201818771T4 (tr) 2019-01-21

Family

ID=39535350

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/18771T TR201818771T4 (tr) 2007-03-06 2008-03-04 Bilişsel Bozuklukların Tedavisinde Kullanıma Yönelik Bileşikler

Country Status (12)

Country Link
US (1) US8623891B2 (tr)
EP (2) EP2131837B1 (tr)
JP (1) JP2010520299A (tr)
AU (3) AU2008222890C1 (tr)
BR (1) BRPI0808353B8 (tr)
CA (1) CA2680324A1 (tr)
DK (1) DK2481407T3 (tr)
ES (2) ES2711075T3 (tr)
HK (1) HK1139855A1 (tr)
PT (1) PT2481407T (tr)
TR (1) TR201818771T4 (tr)
WO (1) WO2008109610A1 (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028654T2 (en) * 2005-01-26 2016-12-28 Allergan Inc 3-aryl-3-hydroxy-2-aminopropionic amides, 3-heteroaryl-3-hydroxy-2-aminopropionic amides and related compounds having analgesic and / or immunostimulating activity
KR20100047261A (ko) * 2007-07-17 2010-05-07 알러간, 인코포레이티드 불안증 처치 방법
CN102497861A (zh) * 2009-07-17 2012-06-13 阿勒根公司 用于治疗认知障碍的包含胆碱酯酶抑制剂的组合物
CA2774359A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating seizure disorders
BR112012006027A2 (pt) * 2009-09-16 2019-09-24 Allergan Inc composições e métodos para tratar distúrbios de motilidade gastrointestinal.
WO2011034912A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating spasticity
US9242935B2 (en) * 2013-08-15 2016-01-26 Allergan, Inc. (-)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (L)-(+) tartrate salt, its method of production and use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62114946A (ja) 1985-11-13 1987-05-26 Banyu Pharmaceut Co Ltd フエニルセリンアミド誘導体およびそれを有効成分とする中枢神経系用剤
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
GB9909064D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
SE9904197D0 (sv) 1999-11-22 1999-11-22 Amersham Pharm Biotech Ab A method for anion exchange adsorption on matrices carrying mixed mode ligands
BR122015016314B8 (pt) 2001-07-16 2021-05-25 Genzyme Corp método para preparar um composto acíclico, método para preparar um composto amina, método para preparar um composto do tipo esfingosina e método para preparar um composto do tipo ceramida
US6835831B2 (en) 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US20050101674A1 (en) 2003-11-12 2005-05-12 Maurer Barry J. PPMP as a ceramide catabolism inhibitor for cancer treatment
US20060081273A1 (en) * 2004-10-20 2006-04-20 Mcdermott Wayne T Dense fluid compositions and processes using same for article treatment and residue removal
HUE028654T2 (en) * 2005-01-26 2016-12-28 Allergan Inc 3-aryl-3-hydroxy-2-aminopropionic amides, 3-heteroaryl-3-hydroxy-2-aminopropionic amides and related compounds having analgesic and / or immunostimulating activity
WO2008011483A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
WO2008011485A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain

Also Published As

Publication number Publication date
AU2008222890C1 (en) 2016-09-08
ES2711075T3 (es) 2019-04-30
PT2481407T (pt) 2018-12-28
AU2016204334A1 (en) 2016-07-14
AU2016204334B2 (en) 2018-03-15
EP2131837B1 (en) 2012-05-16
AU2018204290B2 (en) 2020-05-21
EP2481407B1 (en) 2018-09-26
BRPI0808353B8 (pt) 2021-05-25
EP2131837A1 (en) 2009-12-16
EP2481407A1 (en) 2012-08-01
JP2010520299A (ja) 2010-06-10
BRPI0808353B1 (pt) 2020-03-31
DK2481407T3 (en) 2019-01-07
AU2018204290A1 (en) 2018-07-05
AU2008222890A1 (en) 2008-09-12
HK1139855A1 (en) 2010-09-30
BRPI0808353A2 (pt) 2014-07-29
WO2008109610A1 (en) 2008-09-12
US20100093793A1 (en) 2010-04-15
CA2680324A1 (en) 2008-09-12
US8623891B2 (en) 2014-01-07
AU2008222890B2 (en) 2016-03-31
ES2383384T3 (es) 2012-06-20

Similar Documents

Publication Publication Date Title
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
ME01992B (me) Jedinjenje diarilhidantoina
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
EA201000050A1 (ru) Замещенные бициклолактамные соединения
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA201000395A1 (ru) Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
TW200745028A (en) Novel sulphonylpyrroles
EA201100794A1 (ru) Замещенные пиримидины, предназначенные для лечения заболеваний, таких как рак
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
TW200745027A (en) Novel sulphonylpyrroles
TR201818771T4 (tr) Bilişsel Bozuklukların Tedavisinde Kullanıma Yönelik Bileşikler
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
TW200738651A (en) Cyclohexyl sulfonamide derivatives
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
MA32505B1 (fr) 5-alcynyl-pyrimidines
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MA35086B1 (fr) Compose de triazolopyridine
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
EA201170344A1 (ru) Азаиндольные ингибиторы iap
MX2009009490A (es) Profarmacos novedosos.
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MX2010001303A (es) Compuestos terapeuticos.
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
EA200901504A1 (ru) Производные пиразолона, как ингибиторы pde4